The Value of PET/CT-Based Radiomics in Predicting Adrenal Metastases in Patients with Cancer

<b>Objectives:</b> Differentiation of adrenal incidentalomas (AIs) remains a challenge in the oncological setting. The aim of the study was to explore the diagnostic efficacy of [18F]Fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET/CT)-based radiomics in identifying adrenal metastases and to compare it with that of conventional PET/CT parameters. <b>Materials:</b> Retrospective analysis was performed on 195 AIs for model construction, nomogram drawing, and internal validation. An additional 30 AIs were collected for external validation of the radiomics model and nomogram. Logistic regression analysis was employed to build models based on clinical and PET/CT routine parameters. The open-source software Python (version 3.7.11) was utilized to process the regions of interest (ROI) delineated by ITK-SNAP, extracting radiomic features. Least absolute shrinkage and selection operator (LASSO) regression analysis was applied for feature selection. Based on the selected features, the optimal model was chosen from ten machine learning algorithms, and the nomogram was constructed. <b>Results:</b> The area under the curve (AUC), sensitivity, specificity, and accuracy of conventional parameters of PET/CT were 0.919, 0.849, 0.892, and 0.844, respectively. XGBoost demonstrated superior diagnostic efficiency among the radiomics models, outperforming those constructed using independent predictors. The AUC, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of XGBoost's internal and external validation were 0.945, 0.932, 0.930, 0.960, 0.970, 0.890 and 0.910, 0.900, 0.860, 1, 1, 0.750. The accuracy, sensitivity, specificity, PPV, and NPV of the nomogram in external validation were 0.870, 0.952, 0.667, 0.870, and 0.857. <b>Conclusions:</b> The radiomics model and conventional PET/CT parameters both showed high diagnostic performance (AUC <i>p</i> > 0.05) in discriminating adrenal metastases from benign lesions, offering a practical, non-invasive approach for clinical assessment.